Bio-Rad Laboratories, Inc. Class A Common Stock vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.01 (market cap $9.43B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.35 (market cap $46.84B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | TTWO | |
|---|---|---|
Market Cap | $9.43B | $46.84B |
Sector | Health | Media |
52-Week High | $356.25 | $262.29 |
52-Week Low | $241.71 | $189.69 |
Enterprise Value | $9.18B | $47.96B |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Take-Two Interactive (TTWO) trades at $253.57, up 2.87% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters despite a net loss, driven by NBA 2K and Grand Theft Auto (GTA) performance. Cash flow improved in 2025 due to financing activities, while debt levels remain elevated. Investor focus centers on the November 2026 GTA VI launch, with preorders termed 'unprecedented' by management (Bloomberg, August 7, 2026).
The outlook hinges on GTA VI's success, offering substantial upside to the $300.55 consensus target, but execution risks and high valuation multiples (P/S 6.94, EV/EBITDA 38.35) warrant caution. Near-term volatility may persist amid earnings uncertainty, though institutional bullishness (78.95% buy ratings) underscores long-term growth potential.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →